M3 Biotechnology raises $15.2M, launches clinical trial for drug that could reverse Alzheimer’s

M3 Biotechnology founder and CEO Leen Kawas. (M3 Biotechnology Photo)

Alzheimer’s remains one of the biggest puzzles in the medical world. It’s a devastating disease that impacts millions of people across the globe, but there are no treatments that can halt or reverse it.

M3 Biotechnology, a Seattle-based biotech startup, is hoping it has the answer to that puzzle. The company just launched its first clinical trial to test a drug it says could halt or reverse the nerve damage that causes Alzheimer’s. It has also raised $15.2 million in new funding to support that work, GeekWire has learned.

 

Read more

More people are taking part in drug trials. Should you?

AFP/Getty Images

Do you know someone who has participated in a clinical drug trial? Years ago, your answer would probably have been no, but that may have changed. In recent years, the number of clinical drug trials has increased dramatically and researchers are looking for participants.

Read more

LabCorp Forms Strategic Partnership with MC10 to Support Adoption of BioStamp Sensor

Global life sciences company LabCorp has formed a strategic collaboration with MC10, a digital health startup developing wearable sensor systems for seamless healthcare data collection. As part of the strategic partnership, LabCorp has also made an equity investment into MC10 to support adoption of it’s proprietary technology for use by LabCorp’s Covance Drug Development business in clinical trials and research studies, with the potential to be adapted over time for use in patient testing and monitoring.

Read more

Actually, Many New Cancer Drugs May Be Helpful And Worth Trying

Shutterstock

You might have heard that many new cancer medicines offer little benefit. This month, the BMJ published a review finding that for most cancer drugs approved by the European Medicines Agency between 2009 and 2013, there was neither published evidence that they extend overall survival nor improve patients’ quality of life. In 2015, JAMA reported similar observations for oncology drugs approved by the U.S. FDA between 2008 and 2012. Both papers focused on evidence from randomized clinical trials.

Read more

Janssen makes iSTEP clinical trials digital platform open to all

Janssen R&D has launched a mobile platform to support patients taking part in clinical trials, and ultimately hope to boost chances of final success in the research. 

Named the Integrated Smart Trial and Engagement Platform, or iSTEP, the platform has been designed to address many of the problems which make taking part in  a clinical trial difficult for a participant.

Significantly, the platform is open to industry use and uses mobile technology, ‘smart’ packaging and electronic labelling of data in an attempt to streamline clinical trial processes and management.

Read more

Medical hub puts state ahead in healthcare services – The Borneo Post

Angie Kueh, the executive director of KHK Development (left) and Baijirui, chairman of Tianjin Tianbei Real Estate, exchanging documents after the Agreement Signing at a hotel in Kuching, witnessed by Dr Sim (centre), Penguang (third left) and Snowdan (third right). — Photos by Sharon Kong

KUCHING: The proposed RM4 billion Integrated International Medical Hub (KIMhub) to be located near the Heart Centre in Kota Samarahan will put Sarawak in the forefront of integrated healthcare services, said Chief Minister Datuk Amar Abang Johari Tun Openg.

He said the KIMhub is expected to be in operation in the next ten years.

Read more

Explainer: how do drugs get from the point of discovery to the pharmacy shelf?

Not every drug designed by pharmaceutical companies makes it to the market; very few do. Only 9.6% of new drugs in development in the years 2006-2015 successfully made it to the market to be used by patients. That’s because there’s quite a process a drug needs to go through to make sure it’s not only effective for what it’s designed for, but that it’s not harmful.

After animal trials, that provide essential information on the effects of the drug on vital organs and how toxic the drug is at different doses, the drug progresses to testing in humans. This is done through a number of clinical trials conducted over four phases.

Read more

AI: Personal Therapy Robots and Other Ways That Machine Learning Is Changing Health Care

Many people worry that robots and artificial intelligence will eliminate jobs, including those in health care. But a little AI might not be unwelcome to people tired of waiting for test results or other improvements to their average experience at the doctor’s office. AI could speed up care, make medications more affordable and give patients more time with their doctors. Here are four ways machine learning is already changing health care.

Read more

New antibody attacks 99% of HIV strains

Scientists have engineered an antibody that attacks 99% of HIV strains and can prevent infection in primates.

It is built to attack three critical parts of the virus – making it harder for HIV to resist its effects.

The work is a collaboration between the US National Institutes of Health and the pharmaceutical company Sanofi.

Read more